Introduction: Sedulo Group recently analyzed clinical trials for unapproved primary immuno-oncology (IO) drugs. Our analysis of global data gathered from multiple trial registries provided a compelling snapshot of the recent IO clinical landscape and prompted several unanswered questions regarding future evolution and the impact on manufacturers competing in the space. Our Approach to this Analysis: We started by analyzing pharma-sponsored …
Accelerated Approval Pathway Part 1
This first article, part of a three-post series, focusses on need for such a meeting and underlines the impact of accelerated approvals in the field of Oncology.